Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011

March 29, 2011 - PRLog -- GlobalData analysis finds that the global bladder cancer therapeutics market is moderately attractive and is primarily driven by growth in the patient volume and growth in the cost of therapy. The patient volume was driven by growth in treatment usage pattern measurements such as diseased population, treatment seeking population, Diagnosed Population and prescription population.

In 2010, the bladder cancer therapeutics market’s key markets (the US, UK, Germany, France, Italy, Spain, Japan, Brazil, Russia, India and China) were collectively worth $610m. The market’s size is driven by two key parameters, namely the patient volume and the annual cost of therapy per patient. Between 2001 and 2010, the global bladder cancer therapeutics market grew at a CAGR of 8.0%.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Bladder-Cancer-Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-Volume-1-2011&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

The bladder cancer therapeutics market is completely dominated by generic drugs such as methotrexate, cisplatin, vinblastin and doxorubicin. BCG (Bacillus Calmette-Guérin) therapy and mitomycin C are the other drugs that are used for the treatment of bladder cancer.

Gemcitabine was the top-selling drug in the bladder cancer therapeutics market in 2010. The other leading drugs in the market in 2001 were BCG therapy and methotrexate which registered sales of $55m and $57m. In 2010, gemcitabine was the leading drug in the bladder cancer therapeutics market, with sales of $170m. Methotrexate and BCG therapy were the other leading therapies with sales of $145m and $131m. Between 2010 and 2020, three promising therapies, Javlor (vinflunine), Urocidin (intravesical formulation of Mycobacterial cell wall-DNA complex (MCC)) and EOquin (apaziquone), are expected to hit the market. Between 2010 and 2020, the market is expected to be led by Urocidin, with forecast sales of $386m.

GlobalData, the industry analysis specialist, has released its new report, “Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume 1 2011”. The report is an essential source of information and analysis on the global bladder cancer therapeutics market. The report provides comprehensive information on bladder cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global bladder cancer therapeutics market. It analyses the treatment usage patterns in the global bladder cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global bladder cancer sector. It quantifies the unmet need in the global bladder cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Blad...

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com            
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.